Sort by
Refine Your Search
-
Malignancies: From Mechanisms to Therapies”. In this CRC we will focus on myeloid malignancies as a model to dissect the various molecular mechanisms that enable and regulate cancer cell plasticity in AML. Our
-
“Cellular Plasticity in Myeloid Malignancies: From Mechanisms to Therapies”. In this CRC we will focus on myeloid malignancies as a model to dissect the various molecular mechanisms that enable and regulate
-
xenograft (PDX) models. To this end, the candidate will have direct access to cutting-edge mass spectrometry and advanced bioinformatics infrastructure. The project is part of the collaborative research
-
“Cellular Plasticity in Myeloid Malignancies: From Mechanisms to Therapies”. In this CRC we will focus on myeloid malignancies as a model to dissect the various molecular mechanisms that enable and regulate
-
of the synthetic peptide in chronic and acute heart failure animal models. The therapeutic peptide is derived from the protein S100A1, which plays a central role in maintaining normal heart function. The synthetic
-
against cardiac diseases. It is based on extensive preliminary work by our working group, which has demonstrated therapeutic effects of the synthetic peptide in chronic and acute heart failure animal models
-
adults, characterised by severe genomic instability and a lack of targeted therapies. Using cutting-edge methods and unique primary patient-derived cell models, this project will seek to understand
-
(CV, motivation letter, 2-3 referees and a copy of Bachelor and Master transcripts) to Elmar Schiebel (schiebel.elmar@zmbh.uni-heidelberg.de ). Mailing address: Prof. Elmar Schiebel, ZMBH, Heidelberg
-
on TV-L scale (E13, 65%). Application deadline: April 30, 2025 Interested? Please send applications (CV, motivation letter, 2-3 referees and a copy of Bachelor and Master transcripts to Axel Mogk (a.mogk